ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1022

TNF-α Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-α Production and Enhancing Th1 and Th17 Cell Differentiation

Antonios Psarras1,2,3, Agne Antanaviciute4, Ian Carr4, Miriam Wittmann1,2, Paul Emery1,5, George C Tsokos6 and Edward M Vital1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, 4Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, 5Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Dendritic cells, innate immunity and interferons, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Innate Immunity Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Human plasmacytoid dendritic cells (pDCs) play a vital role in modulating immune responses. pDCs can produce massive amounts of type I IFNs in response to nucleic acids via toll-like receptors (TLRs) and they are known to possess weak antigen-presenting properties inducing CD4+ T cell activation. Previous data showed a cross-regulation between TNF-α and IFN-α but the effect of TNF-α on pDCs remains unclear. The aim of this study was to investigate how TNF-α regulates the immune function of human pDCs.

Methods: Freshly isolated peripheral blood mononuclear cells were treated with TNF-α, TLR7 and TLR9 synthetic agonists. pDCs were immunophenotyped using flow cytometry. RNA from sorted pDCs was extracted and sequenced using Smart-seq2 for sensitive full-length transcriptome profiling. For pDC/T cell co-culture, fresh or TNF-α-treated pDCs were cultured with naïve CD4+ T cells for 5 days. The production of cytokines was measured by intracellular staining and ELISA.

Results: Upon stimulation with TLR7 and TLR9 agonists, there were three main pDC populations: non-producers, TNF-α-producers, TNF-α/IFN-α-producers. Exogenous TNF-α significantly reduced the production of both IFN-α and TNF-α in TLR9-stimulated pDCs but only IFN-α in TLR7-stimulated pDCs. Neutralization of autologous TNF-α with anti-TNF antibody partially sustained IFN-α secretion by TLR9-stimulated pDCs after 24 hours. Exogenous TNF-α significantly promoted pDC maturation by upregulation of costimulatory molecules and chemokine receptors such as CD80, CD86, HLA-DR, and CCR7. RNA-sequencing data analysis suggested that TNF-α inhibits IFN-α production by interfering with the IRF7 and NFκB pathways but promotes antigen processing and presentation pathways as well as T cell activation and differentiation. Indeed, the in vitro co-culture showed that TNF-α-treated pDCs induced higher CD4+ T cell proliferation and favoured Th1/Th17 polarization.

Conclusion: Although pDCs possess weak antigen-presenting properties, TNF-α can enhance pDC maturation by switching their main role as IFN-α-producing cells to a more conventional DC phenotype. The functional status of pDCs might be strongly influenced by overall inflammatory environment and TNF-α might regulate IFN-α-mediated aspects of a range of autoimmune and inflammatory diseases.


Disclosure: A. Psarras, None; A. Antanaviciute, None; I. Carr, None; M. Wittmann, Novartis, 5,Janssen, 5,AbbVie Inc., 5,Celgene Corporation, 5; P. Emery, Bristol-Myers Squibb, 2, 5,Pfizer, Inc., 2, 5,Roche, 2, 5,Novartis, 5,UCB, Inc., 5,Abbott, 2, 5,Merck & Co., 2; G. C. Tsokos, Janssen, 5,Silicon Pharmaceuticals, 9,ABPRO, 9; E. M. Vital, Roche, 2, 5,GlaxoSmithKline, 2, 5,AstraZeneca, 2, 5.

To cite this abstract in AMA style:

Psarras A, Antanaviciute A, Carr I, Wittmann M, Emery P, Tsokos GC, Vital EM. TNF-α Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-α Production and Enhancing Th1 and Th17 Cell Differentiation [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/tnf-%ce%b1-regulates-plasmacytoid-dendritic-cells-by-suppressing-ifn-%ce%b1-production-and-enhancing-th1-and-th17-cell-differentiation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnf-%ce%b1-regulates-plasmacytoid-dendritic-cells-by-suppressing-ifn-%ce%b1-production-and-enhancing-th1-and-th17-cell-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology